OS Therapies OSTX
NYSE OSTX
$1.59 +0.01 (+0.63%)
At close: Aug 21, 2026 · 4:00 PM EDT

OS Therapies (OSTX) Cash from Investing Activities (2023 - 2025)

OS Therapies' (OSTX) quarterly Cash from Investing Activities came in at -$292787.0 in Q2 2025, down 68.62% on a QoQ basis from -$173636.0 in Q1 2025.

OS Therapies (OSTX) Cash from Investing Activities (2023 - 2025) Analysis & Trends

OS Therapies (OSTX) has 2 years of Cash from Investing Activities data on file, last reported at -$292787.0 in Q2 2025.

  • Quarterly Cash from Investing Activities changed N/A year-over-year to -$292787.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$466423.0 (changed N/A YoY) and the FY2025 annual result came in at -$466423.0, changed N/A from the prior year.
  • Cash from Investing Activities retreated to -$292787.0 in Q2 2025, from -$173636.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1145.0 in Q1 2023 to a low of -$292787.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 329.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -49.35 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -363.46 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -3.17 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 24.51 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -229.72 Mn
10 OS Therapies 19.46 Mn 19.46 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -292,787.00
Jun 30, 2025 -292,787.00
Mar 31, 2025 -173,636.00
Mar 31, 2025 -173,636.00
Dec 31, 2023 19.00
Dec 31, 2023 19.00
Jun 30, 2023 -19.00
Jun 30, 2023 -19.00
Mar 31, 2023 1,145.00
Mar 31, 2023 1,145.00